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an epidemiologic survey is necessary to evaluate and prevent
this illness from affecting persons at risk.
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Brucellosis is a serious health problem because of its severe
complications and its tendency to be a chronic disease [1]. The
most effective and least toxic therapy for human brucellosis is
still questionable. Streptomycin, gentamicin, tetracycline,
doxycycline, rifampin and trimethoprim–sulfamethoxazole are
among the widely used antibiotics in the treatment of human
brucellosis. The use of a single antibiotic is not recommended
because of reduced efficacy. The combination most frequently
recommended is rifampin plus doxycycline for 45 days. Other
recommended regimens are streptomycin plus doxycycline and
rifampin plus trimethoprim–sulfamethoxazole [2–4]. In spite of
these suggested treatments, the relapse rate is still about 10%
[1,3].
The treatment of brucellosis in children (under 6–8 years of
age) is a problem because of tetracycline accumulation in bones
and tooth structures [5]. Brucellosis is also a problem in pregnant
women, since for them the usual drugs are contraindicated [2].
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Erythromycin is not teratogenic and is safe to be used during
pregnancy and for children [5,6]. Therefore, in the treatment
of brucellosis, new antibiotics with better activity and a higher
degree of safety in pregnant women and children are needed.
This study was undertaken to investigate the possibility of ery-
thromycin treatment for brucellosis.
The murine brucellosis model, which is a well-known and
commonly used animal model with reproducibility described
previously, was used in this study [7–9]. In total, 104 male
Balb/c mice (25–30 g) were used. Mice were fed ad libitum
with standard mouse diet. In order to estimate the average
water consumption per day per mouse, water consumption was
measured for a week and daily consumption was calculated for
each mouse.
Brucella melitensis M16 was obtained from The Department of
Microbiology, School of Veterinary Medicine, Firat University.
Minimum inhibitory concentrations (MICs) of antibiotics were
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determined by routine broth microdilution procedures in
microtiter trays. Minimum bactericidal concentrations (MBCs)
were determined by subculture on brucella agar (Becton
Dickinson and Company, Cockeysville, MD, USA) from tubes
showing no turbidity [10].
Bacteria were cultured on brucella agar at 37 °C for 72 h
and then suspended in physiologic saline which contained 4–
8  104 colony-forming units (CFUs) per mL. From this sus-
pension, 0.5 mL was inoculated into each mouse intra-
peritoneally.
Seven days after inoculation, four mice were sacrificed under
ether anaesthesia, and spleen cultures were carried out. All four
mice were found to be infected. Eighty mice were randomly
divided into five groups, each group consisting of 16 mice. Tap
water was given to the first (control) group. Rifampin (Rifadin
oral suspension, Hoechst, Istanbul, Turkey) was given to the
second group, and erythromycin (Erythrocin oral suspension,
Abfar, Fako Drug, Levent, Istanbul, Turkey) to the other three
groups, for 15 days. Rifampin and erythromycin were sus-
pended in tap water, and added to the drinking water. Accord-
ingly, mice were given rifampin 50 mg/kg per day and
erythromycin 50, 100 and 200 mg/kg per day. Fresh drinking
water with antibiotics was prepared daily.
Mice were sacrificed under anaesthesia after 3 days without
treatment; spleens were removed aseptically and homogenized
in 1 mL, of sterile physiologic saline. Volumes of 1 mL, of
undiluted and of three dilutions (l/10, 1/100 and 1/1000) of
the homogenates in physiologic saline were placed onto brucella
agar plates. After 72 h of incubation at 37 °C, Brucella melitensis
colonies were counted. Colonies were evaluated according to
growth characteristics, colony morphology and Gram-staining.
Each procedure was performed in triplicate. The number of
CFUs per plate was calculated, and the results of all four
dilutions were averaged and expressed as mean log10 of Brucella
per mL of homogenate. Plates with no bacterial growth were
incubated for an additional 4 days before being considered ster-
ile. The presence of growth was considered as a failure.
Blood for determination of antibiotic level was collected by
orbital puncture from five mice from each of the four groups.
Blood samples were obtained from each mouse on days 3 and
Table 1 Failure
rates and mean
log CFU of the
control, rifampin- and
erythromycin-
treated groups
Failure
Therapy mg/kg/day n % Mean log CFU
Control 0 16/16 100 4.72
Rifampin 50 0/16a 0 –
Erythromycin 50 9/16a 56.2 4.45
Erythromycin 100 3/16a 18.7 4.56
Erythromycin 200 2/16a 12.5 3.52
a P  0.01 (according to the control group).
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7. The antibiotic levels were determined in duplicate. Blood
was soaked onto a paper disk, and the disk was placed on
agar seeded with appropriate microorganisms for bioassays of
antibiotic concentrations [8,11]. Indicator organisms and media
were Bacillus subtilis ATCC 6633 and antibiotic medium no. 2
(Difco Laboratories, Detroit, MI, USA) for rifampin, and Sar-
cinia lutea ATCC 9341 and antibiotic medium no. 11 (Difco)
for erythromycin [8,11]. Blood levels were calculated by com-
paring the zone of inhibition with a curve of known con-
centrations of the antibiotics.
Statistical evaluation of failure rates was performed using
chi-square and Fisher’s exact tests. Since the number of positive
cultures was low in some groups, no statistical evaluation was
performed for CFUs.
The MIC and MBC values for rifampin were 1 and 2 mg/L,
respectively, and for erythromycin they were 4 and 8 mg/L,
respectively.
In the control group, all spleen cultures were positive on
day 18. In the rifampin-treated group, all spleen cultures were
negative; this result was significantly different from that of the
control group (P  0.000001). Failures were found in nine
(56.2%), three (18.7%) and two mice (12.5%) in groups which
were given erythromycin at doses of 50, 100 and 200 mg/kg,
respectively. These results were statistically different compared
to the control group (P  0.01, P  0.000005, P  0.000001,
respectively). The lowest dose of the erythromycin-treated
group (50 mg/kg per day) was found to be different from
that of the rifampin-treated group (P  0.001), but the other
erythromycin-treated groups (100 and 200 mg/kg per day)
were not found to be statistically different from the rifampin-
treated group (P  0.05) (Table 1).
Mean log CFU was 4.72 in the control group. In positive
cultures of the erythromycin 50, 100 and 200 mg/kg per day
groups, means log CFU were 4.45, 4.56 and 3.52, respectively.
Mean blood levels of antibiotics are shown in Table 2. The
mean blood level of rifampin was 41.6 mg/L in the rifampin-
treated group. The mean blood levels of erythromycin were
0.41, 0.74 and 1.13 mg/L in the 50, 100 and 200 mg/kg per
day groups, respectively.
Over a long period, macrolide antibiotics were investigated
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Table 2 Mean blood levels of antibiotics in the antibiotic-
treated groups
Mean blood antibiotic
Therapy mg/kg/day level (mg/L)
Rifampin 50 41.6
Erythromycin 50 0.41
Erythromycin 100 0.74
Erythromycin 200 1.13
in the treatment of brucellosis. Lang et al. [9] reported that, in
an experimental murine brucellosis, azithromycin cured 10 of
10 mice, whereas roxithromycin cured one of 10 mice. These
authors recommended azithromycin in the treatment of bru-
cellosis in young children and pregnant females. Domingo et al.
[12] reported that a short oral treatment course with azi-
thromycin was able to reduce the infection significantly, but it
was not able to cure the animals as effectively as the classic
regimen with doxycycline administered for a longer period of
time.
Since Brucella spp. are intracellular pathogens, antibiotics
for treatment of brucellosis must have adequate intracellular
concentrations [2]. Also, the antibiotic must be active in vitro
[4]. The macrolide erythromycin is widely used in the treatment
of intracellular pathogens such as Legionella, Chlamydia, Myco-
plasma and Ricketsia [6,13]. Erythromycin diffuses readily into
the intracellular fluids and actively accumulates intracellularly
in polymorphonuclear leukocytes and in alveolar macrophages
[6,14]. To the best of our knowledge, there is no report con-
cerning the in vivo use of erythromycin for the treatment of
brucellosis. Since erythromycin is effective in vivo with good
activity in macrophages, it may be effective in the treatment of
brucellosis. In this study, all spleen-culture results were found
to be positive in the control group, whereas we found that
erythromycin was indeed effective in the treatment of murine
brucellosis at doses of 50, 100 and 200 mg/kg (P  0.01).
Erythromycin blood levels were found to be less than the
MIC value of the strain used in this study, but the con-
centrations of erythromycin detected in alveolar macrophages
and neutrophils were reported to be 9–23 times and 10–13 times
greater than the extracellular fluid concentrations, respectively
[13]. We found mean blood levels of erythromycin of 0.41,
0.74 and 1.13 mg/L and obtained failure rates of 56.2%, 18.7%
and 12.5%, respectively, in groups of mice treated with ery-
thromycin.
Drug efficacy is primarily related to the dose [7,8]. In an
experimental mouse brucellosis, when 1.4, 3, 6, 12.5, 25 and
50 mg/kg per day doses of rifampin were used, the failure
rate was found to be 100%, 82%, 40%, 0%, 12.5% and 0%,
respectively [7]. In the present study, we used rifampin at a
50 mg/kg per day dose and found a failure rate of 0%. We used
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erythromycin at doses of 50, 100 and 200 mg/kg per day and
obtained failure rates of 56.2%, 18.7% and 12.5%, respectively.
The MIC of erythromycin was 4 mg/L for the strain used in
this study. Since the reported erythromycin MIC range is 0.2–
16 mg/L [15–17], if the dose of erythromycin is greater than
200 mg/kg per day or if it is used against brucellosis caused by
Brucella strains with low MIC values, the failure rate could be
even lower.
Our results indicate that erythromycin could be an alter-
native choice in the treatment of human brucellosis. It may
offer particular advantages, especially in young children and
pregnant women with brucellosis.
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